Sort by
Search results
PT-Phen™ LRT
Determination of prothrombin time (PT) in human citrated plasma with ready-for-use liquid reagents.
PT-Phen™ LRT
Determination of prothrombin time (PT) in human citrated plasma with ready-for-use liquid reagents.
PT-Phen™ LRT
Determination of prothrombin time (PT) in human citrated plasma with ready-for-use liquid reagents.
PT-Phen™ LRT
Determination of prothrombin time (PT) in human citrated plasma with ready-for-use liquid reagents.
Factor II (Prothrombin) Deficient Plasma
Measurement of factor II (FII / prothrombin) activity in human citrated plasma using a clotting method, triggered with calcium thromboplastin. For any in vitro protocol or research study where a source of human prothrombin deficient plasma is required.
Factor II (Prothrombin) Deficient Plasma
Measurement of Factor II (FII / prothrombin) activity in human citrated plasma using a clotting method, triggered with calcium thromboplastin. For any in vitro protocol or research study where a source of human prothrombin deficient plasma is required.
Factor V Deficient Plasma
Measurement of cactor V (FV / proaccelerin) activity in human citrated plasma using a clotting method, triggered with calcium thromboplastin. For any in vitro protocol or research study where a source of human FV deficient plasma is required
Factor V Deficient Plasma
Measurement of factor V (FV / proaccelerin) activity in human citrated plasma using a clotting method, triggered with calcium thromboplastin. For any in vitro protocol or research study where a source of human FV deficient plasma is required
Factor VII Deficient Plasma
Measurement of factor VII (FVII / proaccelerin) activity in human citrated plasma using a clotting method, triggered with calcium thromboplastin. For any in vitro protocol or research study where a source of human FVII deficient plasma is required
Factor VII Deficient Plasma
Measurement of factor VII (FVII / proaccelerin) activity in human citrated plasma using a clotting method, triggered with calcium thromboplastin. For any in vitro protocol or research study where a source of human FVII deficient plasma is required